Masimo Corporation is a global medical technology company that develops and produces a wide range of monitoring technologies, including measurements, sensors, patient monitors, automation and connectivity solutions. The Companyâ€™s healthcare products and patient monitoring solutions generally incorporate a monitor or circuit board, proprietary single-patient use or reusable sensors, software and/or cables. It primarily sells its healthcare products to hospitals, emergency medical service providers, home care providers, physician offices, veterinarians, long-term care facilities. Its measurement technologies include Measure-through Motion and Low Perfusion pulse oximetry, known as Masimo Signal Extraction Technology (SET) pulse oximetry, and advanced rainbow Pulse CO-Oximetry parameters such as noninvasive hemoglobin (SpHb), alongside many other modalities, including brain function monitoring, hemodynamic monitoring, regional oximetry, capnography and gas monitoring, and others.

Employees

2,200

Sector

Medical Equipment, Supplies & Distribution

More about the company

Quotes

Date	Price	Change	Volume
09/06/26	39.00 R$	+27.16%	254

Delayed Quote Sao Paulo

More quotes

Analysis / Opinion

Masimo CEO talks about partnership with Google and Qualcomm

17 September 2024 at 06:36 am AEST

More analyses

Delayed Sao Paulo Other stock markets 06:09:00 10/06/26 am AEST			5-day change	1st Jan Change
39.00 ^BRL	+27.16%		+27.16%	+60.23%

11/06	Masimo Corporation(NasdaqGS:MASI) dropped from S&P Global BMI Index	CI
11/06	Masimo Corporation(NasdaqGS:MASI) dropped from S&P TMI Index	CI

Market Cap	9.42B 48.73B 8.21B 7.57B 7.12B 13.32B 888B 13.41B 90.05B 34.97B 438B 35.37B 34.61B 1,517B	P/E 2026 *	39.4x	P/E 2027 *	37.3x
Enterprise Value	9.42B 48.73B 8.21B 7.57B 7.12B 13.32B 888B 13.41B 90.05B 34.97B 438B 35.37B 34.61B 1,517B	EV / Sales 2026 *	5.77x	EV / Sales 2027 *	5.41x
Free-Float	66.12%	Yield 2026 *	-	Yield 2027 *	-

11/06	Masimo Corporation(NasdaqGS:MASI) dropped from S&P Global BMI Index	CI
11/06	Masimo Corporation(NasdaqGS:MASI) dropped from S&P TMI Index	CI
11/06	Masimo Corporation(NasdaqGS:MASI) dropped from S&P 1000	CI
11/06	Masimo Corporation(NasdaqGS:MASI) dropped from S&P Healthcare Equipment Select Industry Index	CI
11/06	Masimo Corporation(NasdaqGS:MASI) dropped from S&P 400 Health Care	CI
11/06	Masimo Corporation(NasdaqGS:MASI) dropped from S&P 400	CI
11/06	Masimo Corporation(NasdaqGS:MASI) dropped from S&P Composite 1500	CI
11/06	Masimo Corporation Announces Board and Committee Changes	CI
10/06	Danaher Closes Acquisition of Masimo; Maintains Q2, 2026 Outlook	MT
10/06	Masimo Corporation(NasdaqGM:MASI) dropped from NASDAQ Composite Index	CI
10/06	Masimo Corporation(NasdaqGS:MASI) dropped from Russell Midcap Gro-Dynamic Index	CI
10/06	Masimo Corporation(NasdaqGS:MASI) dropped from Russell 2500 Growth Benchmark	CI
10/06	Masimo Corporation(NasdaqGS:MASI) dropped from Russell 3000 Growth Benchmark	CI

27/03	Raymond James Downgrades Masimo to Market Perform From Outperform	MT
27/03	Analyst recommendations: Brown-Forman, ConocoPhillips, DraftKings, Ge Vernova…
18/02	BTIG Downgrades Masimo to Neutral From Buy	MT
18/11	BofA Securities Initiates Masimo at Neutral With $162 Price Target	MT
18/11	Data Drought Breaks and Markets Brace for the Flood

Masimo Corporation Stock Sao Paulo

Stocks

M2AS34

BRM2ASBDR009

Medical Equipment, Supplies & Distribution

Valuation: Masimo Corporation

Chart: Masimo Corporation

Latest news : Masimo Corporation

Last Transcript: Masimo Corporation

Analysts' recommendations: Masimo Corporation

Press Releases: Masimo Corporation

News in other languages: Masimo Corporation

Quotes and Performance

Course Extremes

Managers and Directors: Masimo Corporation

Medical Equipment

Financials

Company Profile

Quotes

Analysis / Opinion

07/05	Court Of Chancery Enforces Non-Delaware Choice Of Forum In Corporate Governance Contract, Finding Legislature Overrode Key Judicial Precedents	AQ
06/05	Masimo : Quarterly Report for Quarter Ending April 4, 2026 (Form 10-Q)	PU
04/05	Masimo Shareholders Approve Acquisition by Danaher	BU
28/04	Masimo SET® Pulse Oximetry Performed Accurately on Hospitalized Newborns of All Skin Tones in Largest-Ever Prospective Real-World Study	BU
08/04	Masimo Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Masimo Corporation - MASI	BU

30/04	Masimo SET® de oximetría de pulso confirmó su precisión en recién nacidos de todos los tonos de piel, en el mayor estudio prospectivo en condiciones reales realizado hasta la fecha
30/04	Masimo SET®-Pulsoximetrie wurde in der bislang umfangreichsten prospektiven Praxisstudie bei hospitalisierten Neugeborenen aller Hautfarben mit hoher Genauigkeit durchgeführt
30/04	L’oxymétrie de pouls Masimo SET® s’est révélée précise chez les nouveau-nés hospitalisés de toutes les couleurs de peau dans le cadre de la plus grande étude prospective jamais menée en conditions réelles
20/04	Los titulares marcan el paso de los mercados
20/04	Im Bann der Schlagzeilen

1 day	+27.16%
1 week	+27.16%
Current month	+31.45%
1 month	+31.45%
3 months	+60.23%
6 months	+52.22%
Current year	+60.23%

1 month	30.67	39
Current year	29.67	39
1 year	23.68	39
3 years	15.46	39
5 years	15.46	40.88
10 years	15.46	40.88

Manager	Title	Age	Since
Micah Young DFI	Director of Finance/CFO	47	16/10/2017
Daniel Cantillon CTO	Chief Tech/Sci/R&D Officer	-	-
Eli Kammerman IRC	Investor Relations Contact	-	-

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
MASIMO CORPORATION	+27.16%	+27.16%	-	-	9.42B
PENUMBRA, INC.	+0.33%	-0.35%	+23.42%	-6.09%	12.44B
ASAHI INTECC CO., LTD.	-1.66%	-5.74%	+57.10%	+23.51%	5.98B
GETINGE AB	+0.23%	+1.92%	+5.44%	-23.24%	5.61B
MINIMED GROUP, INC.	+4.23%	-4.52%	-	-	3.98B
APT MEDICAL INC.	-2.42%	-1.42%	-31.56%	+13.50%	4.1B
JIANGSU YUYUE MEDICAL EQUIPMENT & SUPPLY CO., LTD.	-2.06%	-2.87%	-30.27%	-26.67%	3.73B
NOVOCURE LIMITED	-20.00%	-19.37%	-15.00%	-67.62%	2.07B
IMPLANTICA AG	+3.49%	+9.89%	+52.08%	+229.10%	1.81B
NAKANISHI INC.	-0.73%	-2.36%	+56.74%	-5.76%	1.55B
Average	+0.84%	-1.38%	+14.74%	+17.09%	4.58B
Weighted average by Cap.	+4.21%	-1.82%	+15.35%	+4.20%

	2026 *	2027 *
Net sales	1.63B 8.44B 1.42B 1.31B 1.23B 2.31B 154B 2.32B 15.6B 6.06B 75.83B 6.13B 6B 263B	1.74B 9.01B 1.52B 1.4B 1.32B 2.46B 164B 2.48B 16.65B 6.47B 80.92B 6.54B 6.4B 280B
Net income	240M 1.24B 209M 193M 181M 339M 22.62B 342M 2.29B 891M 11.15B 901M 882M 38.64B	276M 1.43B 241M 222M 209M 390M 26.03B 393M 2.64B 1.03B 12.83B 1.04B 1.01B 44.46B
Net Debt	-	-